Knowing that mesothelin is expressed in almost all pancreatic ductal adenocarcinomas (157), its potential role as a therapeutic target to induce TLS formation in PDAC warrants further investigation. The gene discussed is MSLN; the disease is pancreatic ductal adenocarcinoma.